Preoperative plasma fibrinogen combined with the platelet-to-lymphocyte ratio (F-PLR) serves as a prognostic indicator in patients with non-small cell lung cancer

术前血浆纤维蛋白原联合血小板与淋巴细胞比值(F-PLR)可作为非小细胞肺癌患者的预后指标。

阅读:3

Abstract

BACKGROUND: The aim of this study was to explore the prognostic significance of the combined plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) score in patients who had undergone radical surgery for non-small cell lung cancer (NSCLC). METHODS: In this study, we retrospectively reviewed the medical records of 214 patients who underwent radical resection for lung cancer. The optimal cut-off values for fibrinogen and the platelet - lymphocyte ratio (PLR) were determined by applying the receiver operating characteristic (ROC) curve and the Youden index. Based on these cut-off values, the patients were categorized into three groups: patients with elevated fibrinogen and PLR were assigned a score of 2; those with either elevated fibrinogen or PLR were assigned a score of 1; and those with neither elevation were assigned a score of 0. The Kaplan-Meier method was utilized to plot the survival curves, and differences among the curves were compared using the log - rank test. Univariate and multivariate analyses were carried out using the Cox proportional hazards model. RESULTS: In this study, the optimal cutoff values were 3.90 for fibrinogen and 213.2 for the PLR. Cox's multifactorial analysis revealed that the implementation of adjuvant therapy after surgery(P<0.001), pathological stage(PStage=IIIA/I=0.041), and F-PLR(PF-PLR=1/0 = 0.006、PF-PLR=2/0 = 0.004)were independent prognostic factors influencing patient survival. Additionally, F-PLR was significantly correlated with the overall survival of NSCLC patients after surgery. CONCLUSIONS: The F-PLR score exhibits a significant association with the prognosis of NSCLC patients and can serve as a biomarker for predicting the prognosis of patients following NSCLC surgery.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。